|
Heart failure
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Its absolute values were approximately 350 fmol/mg cytosolic protein, and its expression was not changed in heart failure. beta-Arrestin-2 levels were too low to be detectable using the same methods. beta ARK levels as determined by enzymatic activity were approximately 20 fmol/mg cytosolic protein (beta ARK-1 plus beta ARK-2) and thus almost 20-fold lower than those of beta-arrestin. beta ARK levels were increased approximately twofold in heart failure.(ABSTRACT TRUNCATED AT 250 WORDS)
|
8293560 |
1994 |
|
Congestive heart failure
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Its absolute values were approximately 350 fmol/mg cytosolic protein, and its expression was not changed in heart failure. beta-Arrestin-2 levels were too low to be detectable using the same methods. beta ARK levels as determined by enzymatic activity were approximately 20 fmol/mg cytosolic protein (beta ARK-1 plus beta ARK-2) and thus almost 20-fold lower than those of beta-arrestin. beta ARK levels were increased approximately twofold in heart failure.(ABSTRACT TRUNCATED AT 250 WORDS)
|
8293560 |
1994 |
|
Thyroid Nodule
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The increased beta-arrestin 2 expression in TTNs and the desensitization of the TSH receptor by beta-arrestin 2 in vitro suggest that the beta-arrestin 2 expression is cAMP dependent and that beta-arrestin 2 very likely desensitizes the constitutively activated TSH receptor in toxic thyroid nodules.
|
11119705 |
2000 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In vivo experiments showed that ADV.ARR(2)PB-iCasp9 induced apoptosis in LNCaP but not in HuH-7 xenograft tumors in an AP20187-dependent manner.Furthermore, a simple i.p. injection of AP20187 dramatically suppressed LNCaP tumor growth in nude mice and led to a significantly increased host survival.
|
11559553 |
2001 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We have recently developed a replication-deficient adenovirus carrying the human NIS cDNA linked to a composite probasin promoter, ARR(2)PB, aiming toward specific expression of the human NIS gene (h-NIS) in prostate tissue for targeted radioactive iodide therapy of prostate cancer (Ad-ARR(2)PB/hNIS).
|
14633711 |
2003 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We have recently developed a replication-deficient adenovirus carrying the human NIS cDNA linked to a composite probasin promoter, ARR(2)PB, aiming toward specific expression of the human NIS gene (h-NIS) in prostate tissue for targeted radioactive iodide therapy of prostate cancer (Ad-ARR(2)PB/hNIS).
|
14633711 |
2003 |
|
Prostatic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Lv-ARR(2)PB may be an ideal vector for prostate-tumor targeting and for persistent, hormone-enhanced expression of a therapeutic gene to treat slow growing prostate tumors.
|
15065085 |
2004 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
We therefore conducted a genetic case-control association analysis of the gene for ARRB2 with schizophrenia and METH use disorder in a Japanese population (547 people with schizophrenia, 177 with METH use disorder and 546 controls).
|
17233643 |
2007 |
|
Mood Disorders
|
0.310 |
Biomarker
|
group |
PSYGENET |
Deficient beta-arrestin-2-CRF(1) receptor interactions could contribute to the pathophysiology of affective disorders by inducing excessive CRF(1) receptor signaling.
|
17363685 |
2007 |
|
Mood Disorders
|
0.310 |
Biomarker
|
group |
BEFREE |
Deficient beta-arrestin-2-CRF(1) receptor interactions could contribute to the pathophysiology of affective disorders by inducing excessive CRF(1) receptor signaling.
|
17363685 |
2007 |
|
Amphetamine-Related Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia.
|
17233643 |
2007 |
|
Amphetamine Addiction
|
0.300 |
Biomarker
|
disease |
CTD_human |
Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia.
|
17233643 |
2007 |
|
Amphetamine Abuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia.
|
17233643 |
2007 |
|
Herpes Simplex Infections
|
0.020 |
Biomarker
|
group |
BEFREE |
The aim of the present study was to determine whether a prostate-specific amplicon, containing a probasin-derived promoter (ARR(2)PB) upstream of an essential Herpes simplex virus-1 (HSV-1) viral gene, infected-cell polypeptide 4 (ICP4), could complement an HSV-1 helper virus with this gene deleted (ICP4-) and cause lytic replication specifically in prostate cancer cells.
|
17479106 |
2007 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia.
|
19049562 |
2008 |
|
Bipolar Disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Here we show that lithium, a pharmacological agent used for the management of psychiatric disorders such as bipolar disorder, schizophrenia, and depression, regulates Akt/glycogen synthase kinase 3 (GSK3) signaling and related behaviors in mice by disrupting a signaling complex composed of Akt, beta-arrestin 2, and protein phosphatase 2A.
|
18191226 |
2008 |
|
Mental Depression
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Here we show that lithium, a pharmacological agent used for the management of psychiatric disorders such as bipolar disorder, schizophrenia, and depression, regulates Akt/glycogen synthase kinase 3 (GSK3) signaling and related behaviors in mice by disrupting a signaling complex composed of Akt, beta-arrestin 2, and protein phosphatase 2A.
|
18191226 |
2008 |
|
Depressive disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Here we show that lithium, a pharmacological agent used for the management of psychiatric disorders such as bipolar disorder, schizophrenia, and depression, regulates Akt/glycogen synthase kinase 3 (GSK3) signaling and related behaviors in mice by disrupting a signaling complex composed of Akt, beta-arrestin 2, and protein phosphatase 2A.
|
18191226 |
2008 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We found that the xenograft tumor initiated earlier and grew more rapidly in beta-Arr1 transgenic mice than in both the beta-Arr2 transgenic and wild-type mice after inoculating murine liver cancer Hepa1-6 cells or lymphoma EL4 cells.
|
17890288 |
2008 |
|
Mental disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Here we show that lithium, a pharmacological agent used for the management of psychiatric disorders such as bipolar disorder, schizophrenia, and depression, regulates Akt/glycogen synthase kinase 3 (GSK3) signaling and related behaviors in mice by disrupting a signaling complex composed of Akt, beta-arrestin 2, and protein phosphatase 2A.
|
18191226 |
2008 |
|
Dyskinetic syndrome
|
0.010 |
GeneticVariation
|
disease |
LHGDN |
The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia.
|
19049562 |
2008 |
|
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
We found that the xenograft tumor initiated earlier and grew more rapidly in beta-Arr1 transgenic mice than in both the beta-Arr2 transgenic and wild-type mice after inoculating murine liver cancer Hepa1-6 cells or lymphoma EL4 cells.
|
17890288 |
2008 |
|
Nicotine Dependence
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In summary, our results provide the first evidence of a significant association for ARRB1 and ARRB2 variants with ND in an EA sample.
|
17579607 |
2008 |
|
Abnormal behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
When administered to beta-arrestin 2 knockout mice, lithium fails to affect Akt/GSK3 signaling and induce behavioral changes associated with GSK3 inhibition as it does in normal animals.
|
18191226 |
2008 |
|
Tardive Dyskinesia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Typical antipsychotics are commonly binding to the dopamine receptor D2 (DRD2), but the occurrence of antipsychotic-induced TD is rather delayed; therefore, the development of TD may be associated with mediators or signalling complexes behind DRD2, such as beta-arrestin 2 (ARRB2), an important mediator between DRD2 and serine-threonine protein kinase (AKT) signal cascade.
|
19049562 |
2008 |